瘧疾疫苗市場規模、佔有率和成長分析：按疫苗類型、病原體、年齡層、給藥途徑、通路和地區分類－2026-2033年產業預測

2024 年全球瘧疾疫苗市場價值為 59.9 億美元，預計到 2025 年將成長至 80.3 億美元，到 2033 年將成長至 833.7 億美元，在預測期（2026-2033 年）內複合年成長率為 34.0%。

全球瘧疾疫苗市場涵蓋了專注於研發、生產和銷售針對瘧疾原蟲（瘧疾中最致命的種類）疫苗的公司。該市場在對抗瘧疾瘧疾原蟲發揮著至關重要的作用，瘧疾是撒哈拉以南非洲每年超過2億人感染和約60萬人死亡的主要原因。推動市場發展的關鍵因素之一是世界衛生組織（世衛組織）批准了RTS,S/AS01疫苗，這促成了該疫苗在多個非洲國家成功進行臨床試驗。各國政府、衛生組織和投資者之間的合作創造了良好的資金籌措環境，金融機構投入大量資源以加強疫苗的研發和分發。這些資金使生產商能夠擴大生產規模、降低成本並提高疫苗的可及性，從而使像R21/Matrix-M這樣在臨床試驗中顯示出77%有效率的疫苗在競爭激烈的市場中佔據了有利地位。

全球瘧疾疫苗市場成長要素

全球瘧疾疫苗市場的主要促進因素是瘧疾的日益流行，尤其是在熱帶和亞熱帶地區。除了瘧疾病例的增加，抗藥性寄生蟲株的出現也進一步凸顯了有效疫苗接種策略的必要性。世界各國政府和衛生組織正將控制和根除瘧疾列為優先事項，增加了旨在開發創新疫苗的資金和研究舉措。此外，人們日益認知到瘧疾對醫療衛生系統和社區帶來的經濟負擔，這促進了疫苗研發方面的投資，進而推動了瘧疾疫苗市場的成長。

全球瘧疾疫苗市場面臨的限制因素

全球瘧疾疫苗市場的主要限制因素之一是疫苗研發的複雜性以及相關的監管障礙。瘧原蟲株的多樣性及其變異能力為有效疫苗的研發帶來了巨大挑戰。此外，還需要進行大規模臨床試驗以驗證疫苗的安全性和有效性，這使得疫苗研發過程漫長而昂貴。更重要的是，資金和資源分配有限，尤其是在瘧疾流行地區，阻礙了疫苗分發和公眾接受度所需的研發和基礎設施建設，從而限制了瘧疾疫苗市場的整體成長潛力。

全球瘧疾疫苗市場趨勢

全球瘧疾疫苗市場正經歷著向綜合媒介控制模式的動態轉變。這項轉變得益於殺蟲劑處理蚊帳、室內滯留噴灑和環境控制相結合的協同策略，從而加速了疫苗的推廣應用。這一趨勢反映出衛生部門日益認知到，疫苗與現有媒介控制措施結合使用，能夠建構多層次的瘧疾防線。製藥公司與媒介控制機構之間的合作正在簡化介入宣傳活動，增強社區信心，並鼓勵捐助者投資於綜合解決方案。因此，疫苗接種在更廣泛的瘧疾根除策略中扮演越來越重要的角色，並被視為對抗瘧疾的關鍵要素。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 宏觀經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球瘧疾疫苗市場規模：依疫苗類型分類

• 紅血球疫苗接種前
• 血液期疫苗
• 感染阻斷疫苗
• 多階段疫苗

全球瘧疾疫苗市場規模：依病原體分類

• 惡性瘧疾原蟲。
• 間日瘧原蟲瘧疾原蟲
• 按蚊屬

全球瘧疾疫苗市場規模：依年齡層別分類

• 兒童
• 成人

全球瘧疾疫苗市場規模：依給藥途徑分類

• 注射藥物
• 口服

全球瘧疾疫苗市場規模：依通路分類

• 公共衛生計劃
• 民營市場

全球瘧疾疫苗市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• GlaxoSmithKline plc（RTS, S/Mosquirix）
• Sanaria Inc.
• University of Oxford/Serum Institute（R21）
• Novavax Inc.
• Merck & Co. Inc.
• Pfizer Inc.
• Johnson & Johnson（Janssen）
• Bharat Biotech
• Inovio Pharmaceuticals
• Vaxart Inc.
• BioNTech SE
• Moderna Inc.
• Takeda Pharmaceutical
• Institut Pasteur
• Nobelpharma Co.
• Sumaya Biotech
• GenVec Inc.
• Eli Lilly and Company
• AstraZeneca
• Covaxx（United Biomedical）

結論與建議

Global Malaria Vaccines Market size was valued at USD 5.99 Billion in 2024 and is poised to grow from USD 8.03 Billion in 2025 to USD 83.37 Billion by 2033, growing at a CAGR of 34.0% during the forecast period (2026-2033).

The global malaria vaccine market encompasses entities focused on developing, producing, and marketing vaccines targeting Plasmodium parasites, primarily P. falciparum, the most lethal species. This market plays a crucial role in combating malaria, a leading cause of over 200 million infections and around 600,000 fatalities annually in sub-Saharan Africa. A significant driver is the World Health Organization's endorsement of the RTS,S/AS01 vaccine, initiating successful trials in various African nations. Collaborative efforts involving governments, health alliances, and investors foster a robust financial ecosystem, with funding agencies committing considerable resources to enhance development and distribution. This funding allows manufacturers to scale production, reduce costs, and improve accessibility, positioning promising vaccines like R21/Matrix-M-demonstrating 77% efficacy in trials-attractively within a competitive landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Malaria Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Malaria Vaccines Market Segments Analysis

Global malaria vaccines market is segmented by vaccine type, agent, age group, route of administration, distribution channel and region. Based on vaccine type, the market is segmented into Pre-Erythrocytic Vaccines, Blood Stage Vaccines, Transmission-Blocking Vaccines and Multi-Stage Vaccines. Based on agents, the market is segmented into Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species. Based on age groups, the market is segmented into Pediatric and Adult. Based on route of administration, the market is segmented into Injectable and Oral. Based on distribution channels, the market is segmented into Public Health Programs and Private Market. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Malaria Vaccines Market

A key market driver for the global malaria vaccines market is the increasing prevalence of malaria, particularly in tropical and subtropical regions. The rising incidence of malaria cases, coupled with the emergence of drug-resistant strains of the parasite, has intensified the need for effective vaccination strategies. Governments and health organizations are prioritizing malaria control and eradication efforts, leading to increased funding and research initiatives aimed at developing innovative vaccines. Furthermore, heightened awareness of the economic burden of malaria on healthcare systems and communities is driving investment in vaccine development, propelling growth in the malaria vaccines market.

Restraints in the Global Malaria Vaccines Market

One of the key market restraints for the global malaria vaccines market is the complex nature of vaccine development and the regulatory hurdles associated with it. Malaria's diverse strains and the parasite's ability to mutate pose significant challenges for creating effective vaccines. Coupled with the necessity for extensive clinical trials to establish safety and efficacy, the development process can be prolonged and costly. Additionally, limited funding and resource allocation, especially in endemic regions, hamper research and infrastructure required for vaccine distribution and public acceptance, impeding the overall growth potential of the malaria vaccine market.

Market Trends of the Global Malaria Vaccines Market

The Global Malaria Vaccines market is witnessing a dynamic shift towards integrated vector management, where a synergistic approach combining insecticide-treated nets, indoor residual spraying, and environmental control is enhancing vaccine implementation. This trend reflects a growing recognition among health authorities that vaccines, when used in conjunction with existing vector-control measures, create a multi-layered defense against malaria. Collaborative efforts between pharmaceutical companies and vector-control organizations are streamlining intervention campaigns, fostering community trust, and facilitating donor investment in comprehensive solutions. As a result, the market is increasingly centering vaccinations within broader malaria elimination strategies, positioning them as essential components in the fight against the disease.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Malaria Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Pre-Erythrocytic Vaccines
• Blood Stage Vaccines
• Transmission-Blocking Vaccines
• Multi-Stage Vaccines

Global Malaria Vaccines Market Size by Agent & CAGR (2026-2033)

• Market Overview
• Plasmodium Falciparum
• Plasmodium Vivax
• Anopheles Species

Global Malaria Vaccines Market Size by Age Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult

Global Malaria Vaccines Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Injectable
• Oral

Global Malaria Vaccines Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Public Health Programs
• Private Market

Global Malaria Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Agent, Age Group, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Vaccine Type, Agent, Age Group, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Agent, Age Group, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Agent, Age Group, Route of Administration, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Agent, Age Group, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc (RTS,S/Mosquirix)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanaria Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• University of Oxford / Serum Institute (R21)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Institut Pasteur
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nobelpharma Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumaya Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenVec Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covaxx (United Biomedical)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations